Skip navigation

CNS and Ageing

To view session slides please click on the titles below.

Slides are only available for the sessions where we have been granted permission to publish them.

09.40 - Opening Plenary Session


09.45 - Working with AstraZeneca in the CNS field - Timothy Herpin, AstraZeneca

10.15 - The Genetic Basis of Neurodegenerative Disease Institute of Neurology - Professor John Hardy FRS 

11.15 - Approaches to Neuroprotection
Introduction from the Chair, Alan Palmer, MS Therapeutics

11.20 - Innovation at the Academia-Industry Interface to Enhance Translational Research - Mark Tricklebank, Eli Lilly

11.45 - Sapogenins as Neuroprotective Agents - Tim Sharpington, Phytopharm

12.05 -  SEN1500: Targeting β-amyloid Assemblies for Neuroprotection in Alzheimer’s Disease - Mark Treherne, Senexis

12.25 - Leveraging the Scale of International Collaboration Consortia to Inform Drug Discovery and Development - Yves Joanette, CIHR IRSC

14.00 - Addressing Autoimmune Disorders in the CNS
Introduction from the Chair - Michael O’Neill, EOLAS

14.05 - Advances in the therapy of Multiple Sclerosis: Opportunities and Challenges - Christopher Holloway, ERA Consulting

14.30 - In Vitro Models to Assess Neuroprotective Efficacy - Lars Sundstrom, SARTRE

14.50 - ATX-MS-1467 a Peptide-Based Therapeutic Approach to MS - Keith Martin , Apitope

15.10 - Sodium Channel Blockers as Neuroprotectants - Michael Leach, CenTRion Therapeutics

16.00 - Technologies and Models in CNS Drug Development 
Introduction from the Chair - Philip OliverEli Lilly

16.10 - In Vitro and In Vivo BBB Models - Mo Alavijeh, Pharmidex

16.30 - The Use of Clinical PD Models to Accelerate the Development of CNS Drugs Through Phase 1 - John ConnellICON Development Solutions

16.50 - Translational Research in Motor Neurone Diseases - Pamela Shaw, University of Sheffield

17.10 - The Application of Imaging Technologies to Neurodegenerative Disorders - Ian Wilson, GE Healthcare

17.30 - Supporting Innovation and Development to Meet Future Healthcare Demand - Susan Windham-Bannister, Massachusetts Office for Life Sciences, USA